EZH2 and colorectal carcinoma: Typically, spontaneous colorectal tumors derived from UTX-deficient intestines or human CRC organoids with low UTX expression exhibited sensitivity to EZH2 inhibitors, consistent with previous reports in other cancer types [16, 18].